111 related articles for article (PubMed ID: 1632287)
21. Cardioprotective actions of thromboxane receptor antagonism in ischemic atherosclerotic rabbits.
Osborne JA; Lefer AM
Am J Physiol; 1988 Aug; 255(2 Pt 2):H318-24. PubMed ID: 2970233
[TBL] [Abstract][Full Text] [Related]
22. Effect of enalapril or the thromboxane receptor antagonist, daltroban, in rats with subtotal renal ablation.
Brooks DP; Contino LC; Trizna W; Edwards RM; Ohlstein EH; Solleveld HA
J Pharmacol Exp Ther; 1990 Apr; 253(1):119-23. PubMed ID: 2139468
[TBL] [Abstract][Full Text] [Related]
23. Role of endoperoxides in arachidonic acid-induced vasoconstriction in the isolated perfused kidney of the rat.
Quilley J; McGiff JC; Nasjletti A
Br J Pharmacol; 1989 Jan; 96(1):111-6. PubMed ID: 2522332
[TBL] [Abstract][Full Text] [Related]
24. Interference of the thromboxane antagonist SK&F 88046 with platelet activation and subsequent desensitization by arachidonic acid and the thromboxane mimetics U46619 and EP171.
Vargaftig B; Joseph D; Hatmi M
Thromb Res; 1987 May; 46(4):509-17. PubMed ID: 3039684
[TBL] [Abstract][Full Text] [Related]
25. Daltroban, a thromboxane receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium.
Viehman GE; Ma XL; Lefer AM
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):651-6. PubMed ID: 1966110
[TBL] [Abstract][Full Text] [Related]
26. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
27. BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro.
McKenniff MG; Norman P; Cuthbert NJ; Gardiner PJ
Br J Pharmacol; 1991 Nov; 104(3):585-90. PubMed ID: 1839139
[TBL] [Abstract][Full Text] [Related]
28. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Smith EF; Griswold DE; Egan JW; Hillegass LM; DiMartino MJ
J Cardiovasc Pharmacol; 1989 May; 13(5):715-22. PubMed ID: 2472519
[TBL] [Abstract][Full Text] [Related]
29. Adriamycin-related hypertension in pregnant rats: response to a thromboxane receptor antagonist.
Rathaus M; Podjarny E; Pomeranz A; Green J; Bernheim J
Clin Sci (Lond); 1995 Jun; 88(6):623-7. PubMed ID: 7634744
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
31. Bay U 3405 inhibits cerebral vasospasm induced by authentic thromboxane A2.
Braun M; Schrör K
Stroke; 1990 Dec; 21(12 Suppl):IV152-4. PubMed ID: 2260141
[TBL] [Abstract][Full Text] [Related]
32. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
Griswold DE; Egan JW; Earl CQ; Hillegass LM; Marshall PJ; Smith EF
Prog Clin Biol Res; 1989; 301():161-5. PubMed ID: 2529547
[No Abstract] [Full Text] [Related]
33. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
34. Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats.
Smith EF; McDonald J
Pharmacology; 1988; 36(5):340-7. PubMed ID: 3406046
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and thromboxane A2 antagonistic activity of [[1-aryl(or benzyl)-1-(benzenesulfonamido)methyl]phenyl]alkanoic acid derivatives.
Sakurai S; Ogawa N; Suzuki T; Kato K; Ohashi T; Yasuda S; Kato H; Ito Y
Chem Pharm Bull (Tokyo); 1996 Apr; 44(4):765-77. PubMed ID: 8681409
[TBL] [Abstract][Full Text] [Related]
36. Endotoxin priming of thromboxane-related vasoconstrictor responses in perfused rabbit lungs.
Steudel W; Krämer HJ; Degner D; Rosseau S; Schütte H; Walmrath D; Seeger W
J Appl Physiol (1985); 1997 Jul; 83(1):18-24. PubMed ID: 9216939
[TBL] [Abstract][Full Text] [Related]
37. The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor.
Gillard JW; Morton HE; Fortin R; Yoakim C; Girard Y; Lord A; Ethier D; Leveille C; Letts G; Evans J
Prog Clin Biol Res; 1989; 301():579-83. PubMed ID: 2529557
[No Abstract] [Full Text] [Related]
38. Inhibition of prostaglandin D2 clearance in rat hepatocytes by the thromboxane receptor antagonists daltroban and ifetroban and the thromboxane synthase inhibitor furegrelate.
Pestel S; Nath A; Jungermann K; Schieferdecker HL
Biochem Pharmacol; 2003 Aug; 66(4):643-52. PubMed ID: 12906929
[TBL] [Abstract][Full Text] [Related]
39. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
40. The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis.
Thiemermann C; Ney P; Schrör K
Eur J Pharmacol; 1988 Oct; 155(1-2):57-67. PubMed ID: 2977337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
